ORIRGINAL RESEARCH
Evaluation of the Psychopharmacotherapy Rationality in Inpatients with Paranoid Schizophrenia
Author information
- D. I. Malin
- The Serbsky State Scientific Center for Social and Forensic Psychiatry
- D.R. Bulatova
- Moscow Research Institute of Psychiatry, Serbsky National Medical Research Center of Psychiatry and Narcology
- P.V. Ryvkin
- Moscow Research Institute of Psychiatry, Serbsky National Medical Research Center of Psychiatry and Narcology
- Published
- June 30, 2022
- Pages
- 27-32
Abstract
Relevance. The high prevalence of polypharmacy in real treatment practice of patients with schizoprenia and discrepancies in prescribing drugs with existing clinical recommendations necessitate an assessment of the rationality of the psychopharmacological agents use.
Objectives. The aim of the study was to evaluate the rationality of the use of psychotropic drugs in patients with schizophrenia at the stage of inpatient treatment using the Medication Appropriateness Index (MAI).
Material and methods. We studied 40 hospitalized patients with paranoid schizophrenia according to ICD-10 (F 20.0), 26 men and 14 women aged from 20 to 57 years old (mean 34.9 ± 1.72), illness duration varied from 2 to 29 years (mean 8.92 ± 1.02). To assess the rationality of the psychopharmacotherapy and the frequency of polypharmacy the Medication Appropriateness Index (MAI) was used. Side effects of psychopharmacotherapy and their severity were assessed with UKU Side-Effect Rating Scale.
Results. The MAI score ranged from 0 to 13 points (mean 3.95 ± 0.21). In 28 from 40 patients (70 %) the combined antipsychotic treatment was performed with use of two or more antipsychotics belonged to the first generation and second generations. The most frequent side effects were metabolic and neuroendocrine disorders. Comparative analysis of patients treated with one antipsychotic and patients with two or more antipsychotics showed more frequent side effects, including an increase in the QT interval, in the group of patients with combined antipsychotic therapy.
Conclusion. The MAI is an effective tool to evaluate the rationality of antipsychotic polypharmacy in patients with paranoid schizophrenia.
Keywords
- schizophrenia
- antipsychotics
- antipsychotic polypharmacy
- side effects
How to Cite
References
- Мосолов С.Н., Цукарзи Э.Э., Капилетти С.Г. Антипсихотическая фармакотерапия шизофрении: от научных данных к клиническим рекомендациям. Доказательная медицина – клинической практике // Биологические методы терапии психических расстройств / под ред. С.Н. Мосолова. – М.: Социально-политическая мысль, 2012. – С. 11–61
- Незнанов Н.Г., Мосолов С.Н., Иванов М.В. Психофармакотерапия // Психиатрия: национальное руководство / под ред. Н.Г. Незнанова, Ю.А. Александровского. – М.: ГЭОТАРМедиа, 2018. – 976 с. – С. 820–893
- Костюк Г.П., Шмуклер А.Б., Голубев С.А. и др. Эпидемиологические аспекты диагностики шизофрении в Москве // Социальная и клиническая психиатрия. – 2017. – № 3. – С. 5–9.
- Westaway K., Sluggett J., Alderman C. et al. Prevalence of multiple antipsychotic use and associated adverse effects in Australians with mental illness // Int J Evid-Based Healthc. – 2016. – Vol. 14 (3). – Pp. 104–112. – DOI: https://doi.org/10.1097/XEB.0000000000000082
- Correll C.U., Rummel C., Kluge C. Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials // Schizophr Bull. – 2009. – Vol. 35 (2). – Рp. 443–457. – DOI: https://doi.org/10.1093/schbul/sbn018
- Fleischhacker W.W., Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia // Int J Neuropsychopharmacol. – 2014. – Vol. 17 (7). – Pp. 1083– 1093. – DOI: https://doi.org/10.1017/S1461145712000399D
- Ijaz S., Bolea B., Davies S. et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews // BMC Psychiatry. – 2018. – Vol. 18. – P. 275. – DOI: https://doi.org/10.1176/appi.focus.18307
- Paton C., Whittington C., Barnes T.R. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis // J Clin Psychopharmacol. – 2007. – Vol. 27 (2). – Pp. 198–204. – DOI: https://doi.org/10.1097/JCP.0b0
- Сычев Д.А. Полипрагмазия в клинической практике: проблемы и решения. – М.: ГБОУ ДПО РМАПО, 2016. – 249 с
- Hiroyoshi T., Takefumi S., Gary R., Hiroyuki U. Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review // Can J Psychiatry. – 2015. –Vol. 60 (5). – Pp. 215– 220. – DOI: https://doi.org/10.1177/07067437150600050
- Мосолов С.Н., Малин Д.И., Рывкин П.В., Сычев Д.А. Лекарственные взаимодействия препаратов, применяемых в психиатрической практике // Современная терапия психических расстройств. 2019. – № S1. – С. 2–35. – DOI: https://doi.org/10.21265/PSYPH.2019.50.40828
- Hanlon J.T., Schmader K.E., Samsa G.P. et al. A method for assessing drug therapy appropriateness // Clin Epidemiol. – 1992. – Vol. 45 (10). – Pp. 1045–1051. – DOI: https://doi.org/10.1016/0895-4356(92)90144-c
- Сычев Д.А., Сосновский Е.Е., Отделенов В.А. Индекс рациональности применения лекарственного средства как метод борьбы с полипрагмазией // Клиническая фармакология и терапия. – 2016. – № 3. – С. 78–82.
- Lindstrom E., Lewander T. UKU-SERS-Pat: The UKU side effect self-rating scale. 2002. Available at: https://www.researchgate.net/publication/247241175_UKU-SERSPat_-_the_UKU_side_effect_self-rating_scale (accessed January 19, 2020).
- Федеральное руководство по использованию лекарственных средств (формулярная система). – 9-е изд., перераб. и доп. / под ред. А.Г. Чучалина, Ю.Б. Белоусова, В.В. Яснецова. – М., 2009.
- Федеральное руководство по использованию лекарственных средств (формулярная система). – Вып. XIII / под ред. А.Г. Чучалина, В.В. Яснецова. – М., 2012.
- Malin D.I., Ryvkin P.V. Klinicheski znachimye lekarstvennye vzaimodeistviya pri lechenii antipsikhotikami vtorogo pokoleniya // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2021. – № 2. – S. 36–45. – DOI: https://doi.org/10.21265/PSYPH.2021.57.2.005
- Avrutskii G.Ya., Neduva A.A. Lechenie psikhicheski bol’nykh. – M.: Meditsina, 1988. – 528 s
- Glassman A., Bigger J. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death // Am. J. Psychiatry. – 2001. – Vol. 158. – Pp. 1774–1782. – DOI: https://doi.org/10.1176/appi.ajp.158.11.1774
- Federal’noe rukovodstvo po ispol’zovaniyu lekarstvennykh sredstv (formulyarnaya sistema). Vyp. IV / pod red. A.G. Chuchalina. – M., 2003.